QUARTERLY REPORT

Q1 2021 — Quarterly report

Q1 2021PDF · 30 pages134 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
È 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED March 31, 2021
or
‘ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM 	TO
Commission File Number: 1-10864
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
Delaware 	41-1321939
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota 	55343
(Address of principal executive offices) 	(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $.01 par value 	UNH 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 	Yes È 	No ‘
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit such files). 	Yes È 	No ‘
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer 	È 	Accelerated filer ‘ 	Non-accelerated filer 	‘
Smaller reporting company 	‘ 	Emerging growth company ‘
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ‘
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). 	Yes ‘ 	No È
As of April 30, 2021, there were 943,702,120 shares of the registrant’s Common Stock, $.01 par value per share, issued
and outstanding.

-- 1 of 30 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. 	Financial Statements (unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1
Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 . . . . . . . 	1
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2021
and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2
Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended
March 31, 2021 and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3
Condensed Consolidated Statements of Changes in Equity for the Three Months Ended
March 31, 2021 and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31,
2021 and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5
Notes to the Condensed Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6
1. Basis of Presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6
2. Investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7
3. Fair Value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	9
4. Medical Costs Payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10
5. Short-Term Borrowings and Long-Term Debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11
6. Commitments and Contingencies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12
7. Segment Financial Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	14
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . . 	15
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	25
Item 4. 	Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	25
Part II. Other Information
Item 1. 	Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26
Item 1A. Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26
Item 6. 	Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	27
Signatures 	. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	28

-- 2 of 30 --

PART I
ITEM 1. 	FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data) March 31,
2021 December 31,
2020
Assets
Current assets:
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	19,955 	$ 	16,921
Short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,962 	2,860
Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	15,980 	12,870
Other current receivables, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,546 	12,534
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,094 	4,076
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,971 	4,457
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	59,508 	53,718
Long-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	42,406 	41,242
Property, equipment and capitalized software, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,496 	8,626
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	72,162 	71,337
Other intangible assets, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,842 	10,856
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,757 	11,510
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	205,171 	$ 	197,289
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	24,833 	$ 	21,872
Accounts payable and accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	22,997 	22,495
Short-term borrowings and current maturities of long-term debt . . . . . . . . . . . . . 	8,838 	4,819
Unearned revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,612 	2,842
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	21,361 	20,392
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	80,641 	72,420
Long-term debt, less current maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	37,420 	38,648
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,602 	3,367
Other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12,926 	12,315
Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	134,589 	126,750
Commitments and contingencies (Note 6)
Redeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,269 	2,211
Equity:
Preferred stock, $0.001 par value — 10 shares authorized; no shares issued or
outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	—
Common stock, $0.01 par value — 3,000 shares authorized; 944 and 946 issued
and outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10 	10
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	—
Retained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	71,220 	69,295
Accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,826) 	(3,814)
Nonredeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,909 	2,837
Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	69,313 	68,328
Total liabilities, redeemable noncontrolling interests and equity . . . . . . . . . . . . . . 	$ 	205,171 	$ 	197,289
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
March 31,
(in millions, except per share data) 	2021 	2020
Revenues:
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	55,486 	$ 	50,640
Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,340 	8,431
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,918 	4,985
Investment and other income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	452 	365
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	70,196 	64,421
Operating costs:
Medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	44,904 	41,000
Operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,223 	10,015
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,572 	7,687
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	758 	723
Total operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	63,457 	59,425
Earnings from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,739 	4,996
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(397) 	(437)
Earnings before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,342 	4,559
Provision for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,364) 	(1,094)
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,978 	3,465
Earnings attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(116) 	(83)
Net earnings attributable to UnitedHealth Group common shareholders . . . . . . . . 	$ 	4,862 	$ 	3,382
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	5.14 	$ 	3.56
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	5.08 	$ 	3.52
Basic weighted-average number of common shares outstanding . . . . . . . . . . . . . . . . 	945 	949
Dilutive effect of common share equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12 	13
Diluted weighted-average number of common shares outstanding . . . . . . . . . . . . . . 	957 	962
Anti-dilutive shares excluded from the calculation of dilutive effect of common share
equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3 	10
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
March 31,
(in millions) 	2021 	2020
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 4,978 	$ 3,465
Other comprehensive loss:
Gross unrealized losses on investment securities during the period . . . . . . . . . . . . . 	(764) 	(349)
Income tax effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	174 	80
Total unrealized losses, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(590) 	(269)
Gross reclassification adjustment for net realized gains included in net earnings . . 	(7) 	(18)
Income tax effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2 	4
Total reclassification adjustment, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(5) 	(14)
Total foreign currency translation losses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(417) 	(1,499)
Other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,012) 	(1,782)
Comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,966 	1,683
Comprehensive income attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . 	(116) 	(83)
Comprehensive income attributable to UnitedHealth Group common shareholders . . . 	$ 3,850 	$ 1,600
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Accumulated Other Comprehensive
Income (Loss)
Three months ended March 31,
(in millions)
Common Stock Additional
Paid-In
Capital Retained
Earnings
Net
Unrealized
Gains
(losses)
on Investments
Foreign
Currency
Translation
Losses
Nonredeemable
Noncontrolling
Interests Total
Equity	Shares Amount
Balance at January 1, 2021 . . . . . . . . . . 	946 $ 	10 $ 	— $ 69,295 	$ 	1,336 	$ 	(5,150) $ 	2,837 $ 68,328
Net earnings . . . . . . . . . . . . . . . . . . . . . 	4,862 	80 	4,942
Other comprehensive loss . . . . . . . . . . 	(595) 	(417) 	(1,012)
Issuances of common stock, and
related tax effects . . . . . . . . . . . . . . . 	3 	— 	256 	256
Share-based compensation . . . . . . . . . . 	242 	242
Common share repurchases . . . . . . . . . 	(5) 	— 	— 	(1,650) 	(1,650)
Cash dividends paid on common shares
($1.25 per share) . . . . . . . . . . . . . . . . 	(1,181) 	(1,181)
Redeemable noncontrolling interests
fair value and other adjustments . . . . 	(498) 	(106) 	(604)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests . . . . . . . . . . . . . . . . . . . . . . . 	66 	66
Distribution to nonredeemable
noncontrolling interests . . . . . . . . . . 	(74) 	(74)
Balance at March 31, 2021 . . . . . . . . . . 	944 $ 	10 $ 	— $ 71,220 	$ 	741 	$ 	(5,567) $ 	2,909 $ 69,313
Balance at January 1, 2020 . . . . . . . . . . 	948 $ 	9 $ 	7 $ 61,178 	$ 	589 	$ 	(4,167) $ 	2,820 $ 60,436
Adjustment to adopt ASU 2016-13 . . . 	(28) 	(28)
Net earnings . . . . . . . . . . . . . . . . . . . . . 	3,382 	59 	3,441
Other comprehensive loss . . . . . . . . . . 	(283) 	(1,499) 	(1,782)
Issuances of common stock, and
related tax effects . . . . . . . . . . . . . . . 	5 	1 	320 	321
Share-based compensation . . . . . . . . . . 	234 	234
Common share repurchases . . . . . . . . . 	(6) 	— 	(510) 	(1,181) 	(1,691)
Cash dividends paid on common shares
($1.08 per share) . . . . . . . . . . . . . . . . 	(1,024) 	(1,024)
Redeemable noncontrolling interests
fair value and other adjustments . . . . 	(51) 	(51)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests . . . . . . . . . . . . . . . . . . . . . . . 	50 	50
Distribution to nonredeemable
noncontrolling interests . . . . . . . . . . 	(43) 	(43)
Balance at March 31, 2020 . . . . . . . . . . 	947 $ 	10 $ 	— $ 62,327 	$ 	306 	$ 	(5,666) $ 	2,886 $ 59,863
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended
March 31,
(in millions) 	2021 	2020
Operating activities
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 4,978 	$ 3,465
Noncash items:
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	758 	723
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	341 	202
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	256 	231
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(55) 	45
Net change in other operating items, net of effects from acquisitions and changes in AARP
balances:
Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,895) 	(2,652)
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(955) 	(4,249)
Medical costs payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,968 	1,120
Accounts payable and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	870 	4,137
Unearned revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(261) 	(79)
Cash flows from operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,005 	2,943
Investing activities
Purchases of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,612) 	(3,866)
Sales of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	643 	2,170
Maturities of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,255 	1,726
Cash paid for acquisitions, net of cash assumed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,193) 	(929)
Purchases of property, equipment and capitalized software . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(568) 	(469)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(232) 	(165)
Cash flows used for investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(3,707) 	(1,533)
Financing activities
Common share repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,650) 	(1,691)
Cash dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,181) 	(1,024)
Proceeds from common stock issuances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	436 	557
Repayments of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,150) 	—
Proceeds from short-term borrowings, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,057 	10,797
Customer funds administered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,131 	1,062
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,856) 	(398)
Cash flows from financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	787 	9,303
Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . 	(51) 	(129)
Increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,034 	10,584
Cash and cash equivalents, beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	16,921 	10,985
Cash and cash equivalents, end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$19,955 	$21,569
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 30 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. 	Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and
“the Company”) is a diversified health care company with a mission to help people live healthier lives and help
make the health system work better for everyone. Our two complementary business platforms — Optum and
UnitedHealthcare — are driven by this unified mission and vision to improve health care access, affordability,
experiences and outcomes for the individuals and organizations we are privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally
Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its
subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements,
but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S.
Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would
substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements.
Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated
Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data”
in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC
(2020 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring
adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best
estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for
medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions
and judgments, often because they involve matters that are inherently uncertain and will likely change in
subsequent periods. The impact of any change in estimates is included in earnings in the period in which the
estimate is adjusted.
6

-- 8 of 30 --

2. 	Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
March 31, 2021
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . 	$ 	3,372 	$ 	86 	$ 	(26) 	$ 	3,432
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	6,941 	345 	(22) 	7,264
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	20,395 	533 	(122) 	20,806
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . 	6,784 	185 	(48) 	6,921
Non-U.S. agency mortgage-backed securities . . . . . . . . . . 	2,382 	66 	(19) 	2,429
Total debt securities — available-for-sale . . . . . . . . . . . . . . . . . 	39,874 	1,215 	(237) 	40,852
Debt securities — held-to-maturity:
U.S. government and agency obligations . . . . . . . . . . . . . . 	418 	5 	— 	423
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	31 	2 	— 	33
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	190 	— 	— 	190
Total debt securities — held-to-maturity . . . . . . . . . . . . . . . . . . 	639 	7 	— 	646
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	40,513 	$ 	1,222 	$ (237) 	$ 	41,498
December 31, 2020
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . 	$ 	3,335 	$ 	133 	$ 	(3) 	$ 	3,465
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	6,893 	435 	— 	7,328
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	18,886 	863 	(12) 	19,737
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . 	6,849 	245 	(3) 	7,091
Non-U.S. agency mortgage-backed securities . . . . . . . . . . 	2,116 	95 	(4) 	2,207
Total debt securities — available-for-sale . . . . . . . . . . . . . . . . . 	38,079 	1,771 	(22) 	39,828
Debt securities — held-to-maturity:
U.S. government and agency obligations . . . . . . . . . . . . . . 	420 	6 	— 	426
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	31 	2 	— 	33
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	187 	1 	— 	188
Total debt securities — held-to-maturity . . . . . . . . . . . . . . . . . . 	638 	9 	— 	647
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	38,717 	$ 	1,780 	$ 	(22) 	$ 	40,475
The Company held $2.6 billion and $2.3 billion of equity securities as of March 31, 2021 and December 31,
2020, respectively. The Company’s investments in equity securities primarily consist of employee savings plan
related investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair
values. Additionally, the Company’s investments included $1.3 billion of equity method investments in operating
businesses in the health care sector for both March 31, 2021 and December 31, 2020, respectively. The allowance
for credit losses on held-to-maturity securities at March 31, 2021 and December 31, 2020 was not material.
7

-- 9 of 30 --

The amortized cost and fair value of debt securities as of March 31, 2021, by contractual maturity, were as
follows:
Available-for-Sale 	Held-to-Maturity
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Due in one year or less . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3,037 	$ 	3,053 	$ 	354 	$ 	355
Due after one year through five years . . . . . . . . . . . . . . . . . . . . . . 	12,571 	12,922 	238 	242
Due after five years through ten years . . . . . . . . . . . . . . . . . . . . . . 	10,945 	11,263 	25 	26
Due after ten years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,155 	4,264 	22 	23
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . 	6,784 	6,921 	— 	—
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . 	2,382 	2,429 	— 	—
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	39,874 	$ 	40,852 	$ 	639 	$ 	646
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length
of time that individual securities have been in a continuous unrealized loss position were as follows:
Less Than 12 Months 12 Months or Greater 	Total
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
March 31, 2021
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . $ 	924 	$ (26) 	$ — 	$ 	— $ 	924 	$ (26)
State and municipal obligations . . . . . . . . . . . . . . 	1,141 	(22) 	3 	— 	1,144 	(22)
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . 	5,266 	(120) 	367 	(2) 	5,633 	(122)
U.S. agency mortgage-backed securities . . . . . . . 	2,552 	(48) 	1 	— 	2,553 	(48)
Non-U.S. agency mortgage-backed securities . . . 	650 	(17) 	77 	(2) 	727 	(19)
Total debt securities — available-for-sale . . . . . . . . . . $10,533 	$(233) 	$448 	$ 	(4) $10,981 	$(237)
December 31, 2020
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . $ 	346 	$ 	(3) 	$ — 	$ 	— $ 	346 	$ 	(3)
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . 	1,273 	(9) 	456 	(3) 	1,729 	(12)
U.S. agency mortgage-backed securities . . . . . . . 	601 	(3) 	— 	— 	601 	(3)
Non-U.S. agency mortgage-backed securities . . . 	195 	(1) 	93 	(3) 	288 	(4)
Total debt securities — available-for-sale . . . . . . . . . . $ 2,415 	$ (16) 	$549 	$ 	(6) $ 2,964 	$ (22)
The Company’s unrealized losses from debt securities as of March 31, 2021 were generated from approximately
8,000 positions out of a total of 37,000 positions. The Company believes that it will collect the timely principal
and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses
were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated
with these securities that impacted our assessment on collectability of principal and interest. At each reporting
period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair
value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the
8

-- 10 of 30 --

underlying credit quality and credit ratings of the issuers noting no significant credit deterioration since purchase.
As of March 31, 2021, the Company did not have the intent to sell any of the available-for-sale debt securities in
an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for
credit losses on available-for-sale debt securities at March 31, 2021 and December 31, 2020 was not material.
3. 	Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or
have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and
liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair
value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated
Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2020 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items
measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
March 31, 2021
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	19,880 	$ 	75 	$ 	— 	$ 	19,955
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . . . . 	3,208 	224 	— 	3,432
State and municipal obligations . . . . . . . . . . . . . . . . . 	— 	7,264 	— 	7,264
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . 	29 	20,497 	280 	20,806
U.S. agency mortgage-backed securities . . . . . . . . . . 	— 	6,921 	— 	6,921
Non-U.S. agency mortgage-backed securities . . . . . . 	— 	2,429 	— 	2,429
Total debt securities — available-for-sale . . . . . . . . . . . . . 	3,237 	37,335 	280 	40,852
Equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,975 	27 	— 	2,002
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,753 	2,286 	55 	4,094
Total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	26,845 	$ 	39,723 	$ 	335 	$ 	66,903
Percentage of total assets at fair value . . . . . . . . . . . . . . . . 	40% 	59% 	1% 	100%
December 31, 2020
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	16,841 	$ 	80 	$ 	— 	$ 	16,921
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . . . . 	3,241 	224 	— 	3,465
State and municipal obligations . . . . . . . . . . . . . . . . . 	— 	7,328 	— 	7,328
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . 	25 	19,424 	288 	19,737
U.S. agency mortgage-backed securities . . . . . . . . . . 	— 	7,091 	— 	7,091
Non-U.S. agency mortgage-backed securities . . . . . . 	— 	2,207 	— 	2,207
Total debt securities — available-for-sale . . . . . . . . . . . . . 	3,266 	36,274 	288 	39,828
Equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,795 	33 	— 	1,828
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,774 	2,250 	52 	4,076
Total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	23,676 	$ 	38,637 	$ 	340 	$ 	62,653
Percentage of total assets at fair value . . . . . . . . . . . . . . . . 	38% 	61% 	1% 	100%
There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended
March 31, 2021 or 2020.
9

-- 11 of 30 --

The following table presents a summary of fair value measurements by level and carrying values for certain
financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance
Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
March 31, 2021
Debt securities — held-to-maturity . . . . . . . . . . . . . $ 	463 $ 	110 $ 	73 $ 	646 $ 	639
Long-term debt and other financing obligations . . . . $ 	— $ 	46,315 $ 	— $ 	46,315 $ 	40,903
December 31, 2020
Debt securities — held-to-maturity . . . . . . . . . . . . . $ 	466 $ 	108 $ 	73 $ 	647 $ 	638
Long-term debt and other financing obligations . . . . $ 	— $ 	51,254 $ 	— $ 	51,254 $ 	42,171
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a
nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company
records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded
during either the three months ended March 31, 2021 or 2020.
4. 	Medical Costs Payable
The following table shows the components of the change in medical costs payable for the three months ended
March 31:
(in millions) 	2021 	2020
Medical costs payable, beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 21,872 	$ 21,690
Acquisitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12 	—
Reported medical costs:
Current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	45,914 	41,580
Prior years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,010) 	(580)
Total reported medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	44,904 	41,000
Medical payments:
Payments for current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(25,960) 	(23,471)
Payments for prior years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(15,995) 	(16,447)
Total medical payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(41,955) 	(39,918)
Medical costs payable, end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 24,833 	$ 22,772
For the three months ended March 31, 2021 and March 31, 2020, prior years medical cost reserve development
was primarily driven by lower than expected health system utilization. Medical costs payable included reserves
for claims incurred by insured customers but not yet reported to the Company of $16.3 billion and $14.8 billion
at March 31, 2021 and December 31, 2020, respectively.
10

-- 12 of 30 --

5. 	Short-Term Borrowings and Long-Term Debt
Short-term borrowings and senior unsecured long-term debt consisted of the following:
March 31, 2021 	December 31, 2020
(in millions, except percentages) 	Par Value Carrying
Value 	Fair Value Par Value Carrying
Value 	Fair Value
Commercial paper . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	5,356 $ 	5,355 $ 	5,355 $ 	1,296 $ 	1,296 $ 	1,296
4.700% notes due February 2021 . . . . . . . . . . . . . . 	— 	— 	— 	400 	400 	401
2.125% notes due March 2021 . . . . . . . . . . . . . . . . 	— 	— 	— 	750 	750 	753
Floating rate notes due June 2021 . . . . . . . . . . . . . . 	350 	350 	350 	350 	350 	350
3.150% notes due June 2021 . . . . . . . . . . . . . . . . . . 	400 	400 	402 	400 	400 	405
3.375% notes due November 2021 . . . . . . . . . . . . . 	500 	505 	506 	500 	507 	509
2.875% notes due December 2021 . . . . . . . . . . . . . 	750 	759 	764 	750 	762 	768
2.875% notes due March 2022 . . . . . . . . . . . . . . . . 	1,100 	1,110 	1,120 	1,100 	1,113 	1,127
3.350% notes due July 2022 . . . . . . . . . . . . . . . . . . 	1,000 	999 	1,038 	1,000 	999 	1,048
2.375% notes due October 2022 . . . . . . . . . . . . . . . 	900 	898 	929 	900 	897 	935
0.000% notes due November 2022 . . . . . . . . . . . . . 	15 	14 	14 	15 	14 	14
2.750% notes due February 2023 . . . . . . . . . . . . . . 	625 	641 	648 	625 	644 	654
2.875% notes due March 2023 . . . . . . . . . . . . . . . . 	750 	784 	786 	750 	789 	793
3.500% notes due June 2023 . . . . . . . . . . . . . . . . . . 	750 	748 	801 	750 	748 	809
3.500% notes due February 2024 . . . . . . . . . . . . . . 	750 	747 	813 	750 	747 	821
2.375% notes due August 2024 . . . . . . . . . . . . . . . . 	750 	748 	790 	750 	747 	799
3.750% notes due July 2025 . . . . . . . . . . . . . . . . . . 	2,000 	1,992 	2,214 	2,000 	1,992 	2,279
3.700% notes due December 2025 . . . . . . . . . . . . . 	300 	298 	333 	300 	298 	344
1.250% notes due January 2026 . . . . . . . . . . . . . . . 	500 	496 	500 	500 	496 	515
3.100% notes due March 2026 . . . . . . . . . . . . . . . . 	1,000 	997 	1,086 	1,000 	997 	1,121
3.450% notes due January 2027 . . . . . . . . . . . . . . . 	750 	747 	831 	750 	747 	859
3.375% notes due April 2027 . . . . . . . . . . . . . . . . . 	625 	620 	686 	625 	620 	714
2.950% notes due October 2027 . . . . . . . . . . . . . . . 	950 	941 	1,024 	950 	940 	1,067
3.850% notes due June 2028 . . . . . . . . . . . . . . . . . . 	1,150 	1,144 	1,290 	1,150 	1,143 	1,367
3.875% notes due December 2028 . . . . . . . . . . . . . 	850 	844 	958 	850 	844 	1,019
2.875% notes due August 2029 . . . . . . . . . . . . . . . . 	1,000 	1,015 	1,057 	1,000 	1,086 	1,137
2.000% notes due May 2030 . . . . . . . . . . . . . . . . . . 	1,250 	1,234 	1,226 	1,250 	1,234 	1,326
4.625% notes due July 2035 . . . . . . . . . . . . . . . . . . 	1,000 	992 	1,216 	1,000 	992 	1,340
5.800% notes due March 2036 . . . . . . . . . . . . . . . . 	850 	839 	1,147 	850 	839 	1,271
6.500% notes due June 2037 . . . . . . . . . . . . . . . . . . 	500 	492 	725 	500 	492 	800
6.625% notes due November 2037 . . . . . . . . . . . . . 	650 	642 	959 	650 	641 	1,044
6.875% notes due February 2038 . . . . . . . . . . . . . . 	1,100 	1,077 	1,648 	1,100 	1,077 	1,802
3.500% notes due August 2039 . . . . . . . . . . . . . . . . 	1,250 	1,242 	1,342 	1,250 	1,241 	1,487
2.750% notes due May 2040 . . . . . . . . . . . . . . . . . . 	1,000 	964 	976 	1,000 	964 	1,085
5.700% notes due October 2040 . . . . . . . . . . . . . . . 	300 	296 	412 	300 	296 	451
5.950% notes due February 2041 . . . . . . . . . . . . . . 	350 	346 	494 	350 	346 	540
4.625% notes due November 2041 . . . . . . . . . . . . . 	600 	589 	736 	600 	589 	820
4.375% notes due March 2042 . . . . . . . . . . . . . . . . 	502 	485 	593 	502 	485 	661
3.950% notes due October 2042 . . . . . . . . . . . . . . . 	625 	608 	712 	625 	608 	790
4.250% notes due March 2043 . . . . . . . . . . . . . . . . 	750 	735 	878 	750 	735 	982
4.750% notes due July 2045 . . . . . . . . . . . . . . . . . . 	2,000 	1,974 	2,496 	2,000 	1,974 	2,814
4.200% notes due January 2047 . . . . . . . . . . . . . . . 	750 	738 	875 	750 	738 	991
4.250% notes due April 2047 . . . . . . . . . . . . . . . . . 	725 	718 	847 	725 	717 	963
3.750% notes due October 2047 . . . . . . . . . . . . . . . 	950 	934 	1,031 	950 	934 	1,180
4.250% notes due June 2048 . . . . . . . . . . . . . . . . . . 	1,350 	1,330 	1,592 	1,350 	1,330 	1,803
4.450% notes due December 2048 . . . . . . . . . . . . . 	1,100 	1,087 	1,345 	1,100 	1,086 	1,517
3.700% notes due August 2049 . . . . . . . . . . . . . . . . 	1,250 	1,235 	1,354 	1,250 	1,235 	1,567
2.900% notes due May 2050 . . . . . . . . . . . . . . . . . . 	1,250 	1,208 	1,193 	1,250 	1,208 	1,384
3.875% notes due August 2059 . . . . . . . . . . . . . . . . 	1,250 	1,228 	1,391 	1,250 	1,228 	1,618
3.125% notes due May 2060 . . . . . . . . . . . . . . . . . . 	1,000 	963 	979 	1,000 	965 	1,161
Total short-term borrowings and long-term debt . . $ 45,473 $ 45,108 $ 50,462 $ 42,563 $ 42,280 $ 51,301
11

-- 13 of 30 --

The Company’s long-term debt obligations also included $1.2 billion of other financing obligations as of both
March 31, 2021 and December 31, 2020, of which $359 million and $354 million were classified as current as of
March 31, 2021 and December 31, 2020, respectively.
Short-Term Borrowings
Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through
broker-dealers. As of March 31, 2021, the Company’s outstanding commercial paper had a weighted average
annual interest rate of 0.2%.
The Company has $4.4 billion five-year, $4.4 billion three-year and $3.8 billion 364-day revolving bank credit
facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively.
These facilities provide liquidity support for the Company’s commercial paper program and are available for
general corporate purposes. As of March 31, 2021, no amounts had been drawn on any of the bank credit
facilities. The annual interest rates, which are variable based on term, are calculated based on the London
Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If
amounts had been drawn on the bank credit facilities as of March 31, 2021, annual interest rates would have
ranged from 0.8% to 0.9%.
Debt Covenants
The Company’s bank credit facilities contain various covenants, including covenants requiring the Company to
maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. The Company was in
compliance with its debt covenants as of March 31, 2021.
6. 	Commitments and Contingencies
Pending Acquisitions
The Company has entered into agreements to purchase companies in the health care sector, most notably Change
Healthcare (NASDAQ: CHNG), which is expected to close in the second half of 2021, subject to regulatory
approvals and other customary closing conditions. The total anticipated capital required for these acquisitions,
excluding the payoff of acquired indebtedness, is approximately $12 billion.
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and
regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy
organizations, customers and regulators, relating to the Company’s businesses, including management and
administration of health benefit plans and other services. These matters include medical malpractice,
employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits
coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where
appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently
difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may
involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy;
involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could
result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or
ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be
incurred.
12

-- 14 of 30 --

Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and
reviews. These include routine, regular and special investigations, audits and reviews by the Centers for
Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys
general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the
Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S.
Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the
U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and
other governmental authorities. Similarly, our international businesses are also subject to investigations, audits
and reviews by applicable foreign governments, including South American and other non-U.S. governmental
authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including
for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment
model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits
to validate the coding practices of and supporting documentation maintained by health care providers and such
audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a
lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The
whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper
risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part
and denied in part the Company’s motion to dismiss. In May 2018, DOJ moved to dismiss the Company’s
counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the
court denied the government’s motion for partial summary judgment and dismissed the Company’s
counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this
matter given its procedural status.
13

-- 15 of 30 --

7. 	Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more
information on the Company’s segments see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial
Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2020 10-K.
The following tables present reportable segment financial information:
Optum
(in millions) 	UnitedHealthcare OptumHealth OptumInsight OptumRx Optum
Eliminations 	Optum Corporate and
Eliminations Consolidated
Three Months Ended March 31,
2021
Revenues — unaffiliated customers:
Premiums . . . . . . . . . . . . . . . . . $ 	52,558 $ 	2,928 $ 	— $ 	— $ 	— $ 	2,928 $ 	— $ 	55,486
Products . . . . . . . . . . . . . . . . . . 	— 	8 	37 	8,295 	— 	8,340 	— 	8,340
Services . . . . . . . . . . . . . . . . . . 	2,350 	2,336 	961 	271 	— 	3,568 	— 	5,918
Total revenues — unaffiliated
customers . . . . . . . . . . . . . . . . . . . 	54,908 	5,272 	998 	8,566 	— 	14,836 	— 	69,744
Total revenues — affiliated
customers . . . . . . . . . . . . . . . . . . . 	— 	6,952 	1,821 	13,004 	(475) 	21,302 	(21,302) 	—
Investment and other income . . . . . . 	206 	179 	33 	34 	— 	246 	— 	452
Total revenues . . . . . . . . . . . . . . . . . $ 	55,114 $ 	12,403 $ 	2,852 $ 	21,604 $ 	(475)$ 	36,384 $ 	(21,302)$ 	70,196
Earnings from operations . . . . . . . . . $ 	4,108 $ 	962 $ 	779 $ 	890 $ 	— $ 	2,631 $ 	— $ 	6,739
Interest expense . . . . . . . . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(397) 	(397)
Earnings before income taxes . . . . . $ 	4,108 $ 	962 $ 	779 $ 	890 $ 	— $ 	2,631 $ 	(397)$ 	6,342
Three Months Ended March 31,
2020
Revenues — unaffiliated customers:
Premiums . . . . . . . . . . . . . . . . . $ 	48,593 $ 	2,047 $ 	— $ 	— $ 	— $ 	2,047 $ 	— $ 	50,640
Products . . . . . . . . . . . . . . . . . . 	— 	9 	29 	8,393 	— 	8,431 	— 	8,431
Services . . . . . . . . . . . . . . . . . . 	2,278 	1,548 	891 	268 	— 	2,707 	— 	4,985
Total revenues — unaffiliated
customers . . . . . . . . . . . . . . . . . . . 	50,871 	3,604 	920 	8,661 	— 	13,185 	— 	64,056
Total revenues — affiliated
customers . . . . . . . . . . . . . . . . . . . 	— 	5,452 	1,562 	12,876 	(404) 	19,486 	(19,486) 	—
Investment and other income . . . . . . 	197 	136 	12 	20 	— 	168 	— 	365
Total revenues . . . . . . . . . . . . . . . . . $ 	51,068 $ 	9,192 $ 	2,494 $ 	21,557 $ 	(404) $ 	32,839 $ 	(19,486) $ 	64,421
Earnings from operations . . . . . . . . . $ 	2,888 $ 	712 $ 	536 $ 	860 $ 	— $ 	2,108 $ 	— $ 	4,996
Interest expense . . . . . . . . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(437) 	(437)
Earnings before income taxes . . . . . $ 	2,888 $ 	712 $ 	536 $ 	860 $ 	— $ 	2,108 $ 	(437)$ 	4,559
14

-- 16 of 30 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial
Statements and Notes and with our 2020 10-K, including the Consolidated Financial Statements and Notes in
Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates
otherwise, references to the terms “UnitedHealth Group,” “we,” “our” or “us” used throughout this
Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth
Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management’s
Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding
financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to
differ materially from the results discussed or implied in the forward-looking statements. A description of some
of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2020 10-K and in the discussion
below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a diversified health care company with a mission to help people live healthier lives and
help make the health system work better for everyone. Our two complementary businesses — Optum and
UnitedHealthcare — are driven by this unified mission and vision to improve health care access, affordability,
experiences and outcomes for the individuals and organizations we are privileged to serve.
We have four reportable segments across our two business platforms, Optum and UnitedHealthcare:
• 	OptumHealth;
• 	OptumInsight;
• 	OptumRx; and
• 	UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare
Medicare & Retirement, UnitedHealthcare Community & State and UnitedHealthcare Global.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 10-K and additional
information on our segments can be found in this Item 2 and in Note 7 of Notes to the Condensed Consolidated
Financial Statements included in Part I, Item 1 of this report.
COVID-19 Trends and Uncertainties
The COVID-19 pandemic continues to evolve and the ultimate impact on our business, results of operations,
financial condition and cash flows remains uncertain. During the three months ended March 31, 2021, overall
care activity, including COVID-19 related care, was nearly at seasonal baselines. This was primarily the result of
temporary deferral of elective care activity, which generally tracked with COVID-19 incidence rates during the
quarter. For the three months ended March 31, 2021, the temporary deferral of care was more than offset by
COVID-19 related care and testing costs, rebate requirements, and general economic impacts, such as impacts of
unemployment. The temporary deferral of care, along with continued COVID-19 related care costs, may cause
care patterns to moderately exceed normal baselines in future periods as utilization of health system capacity
15

-- 17 of 30 --

increases and consumers resume elective care. From time to time, health system capacity may be subject to
possible increased volatility due to the pandemic. Specific trends and uncertainties related to our two business
platforms are as follows:
Optum. COVID-19 related care costs continued to impact our OptumHealth risk-based care delivery businesses,
which were partially offset by the continued temporary deferral of care. The temporary deferral of care reduced
fee-for-service care delivery volume, as well as OptumInsight and OptumRx volume-based business activity. We
believe COVID-19 will continue to influence customer and consumer behavior, both during and after the
pandemic, which could impact how care is delivered and the manner in which consumers wish to receive their
prescription drugs or infusion services. We expect COVID-19 related care costs and other economic impacts to
only partially be offset by temporary deferrals of care in the second half of the year as health systems return to
seasonally adjusted levels of care. As a result of the dynamic situation and broad-reaching impact to the health
system, the ultimate impact of COVID-19 on our Optum businesses is uncertain.
UnitedHealthcare. In 2021, we have continued expanded benefit coverage in areas such as COVID-19 related care
and testing, telemedicine, and pharmacy; continuing to assist our customers, care providers, members and
communities in addressing the COVID-19 crisis. Temporary care deferrals continued to impact UnitedHealthcare’s
results of operations for the three months ended March 31, 2021, offset by COVID-19 related care and testing,
rebate requirements and other revenue impacts and broader economic impacts. Enrollment in our commercial
products declined primarily due to employer actions in response to the pandemic.
Increased consumer demand for care, potentially even higher acuity care, along with continued COVID-19
related care and testing costs are expected to result in increased future medical costs in the second half of the
year. Disrupted care patterns, as a result of the pandemic, have and may continue to temporarily affect the ability
to obtain complete member health status information, impacting revenue in businesses utilizing risk adjustment
methodologies. The ultimate overall impact is uncertain and dependent on the future pacing and intensity of the
pandemic, the duration of policies and initiatives to address COVID-19, and general economic uncertainty.
Business Trends
Our businesses participate in the United States, South American and certain other international health markets.
Overall spending on health care is impacted by inflation; utilization; medical technology and pharmaceutical
advancement; regulatory requirements; demographic trends in the population; and national interest in health and
well-being. The rate of market growth may be affected by a variety of factors, including macro-economic
conditions, such as the impacts of COVID-19, and regulatory changes, which could impact our results of
operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs,
including any potential impacts from COVID-19. We frequently evaluate and adjust our approach in each of the
local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and
environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio
(MLR) thresholds and similar revenue adjustments. We will continue seeking to balance growth and profitability
across all these dimensions.
The commercial risk market remains highly competitive in both the small group and large group segments. We
expect broad-based competition to continue as the industry adapts to individual and employer needs amid reform
changes.
Government programs in the community and senior sector tend to receive lower rates of increase than the
commercial market due to governmental budget pressures and lower cost trends.
16

-- 18 of 30 --

Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization
and prescription drug costs. COVID-19 related care and testing costs as well as the deferral of care have also
impacted medical cost trends in the current year and may continue in future years. We endeavor to mitigate those
increases by engaging physicians and consumers with information and helping them make clinically sound
choices, with the objective of helping them achieve high quality, affordable care. The continued uncertain impact
of COVID-19 may impact our ability to estimate medical costs payable, which has resulted in, and could result
in, increased variability to medical cost reserve development.
Regulatory Trends and Uncertainties
Following is a summary of management’s view of regulatory trends and uncertainties. For additional information
regarding regulatory trends and uncertainties, see Part I, Item 1 “Business—Government Regulation,” Part 1,
Item 1A, “Risk Factors,” Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in our 2020 10-K and “Risk Factors” in Part II, Item 1A of this report.
Medicare Advantage Rates. Final 2022 Medicare Advantage rates resulted in an increase in industry base rates
of approximately 4.1%, short of the industry forward medical cost trend. We continue to manage costs through
improving and expanding our coordinated care models, value-based care arrangements and various consumer
engagement tools.
Affordable Care Act (ACA) Tax. The Health Insurance Tax was permanently repealed by Congress, effective
January 1, 2021. The permanent repeal of the tax impacts year-over-year comparability of our financial
statements, including revenues, operating costs, medical care ratio (MCR), operating cost ratio, effective tax rate
and cash flows from operations.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select first quarter 2021 year-over-year operating comparisons to first quarter 2020.
• 	Consolidated revenues grew 9%, UnitedHealthcare revenues grew 8% and Optum revenues grew 11%.
• 	UnitedHealthcare served 1.1 million more people domestically, driven by growth in community and
senior programs, partially offset by decreased people served by our commercial benefits business.
• 	Consolidated earnings from operations increased 35%, including increases of 42% at UnitedHealthcare
and 25% at Optum.
• 	Diluted earnings per common share increased 44% to $5.08.
• 	Cash flows from operations for the three months ended March 31, 2021 were $6.0 billion.
• 	Return on equity was 29.5%.
17

-- 19 of 30 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data)
Three Months Ended
March 31, Increase/
(Decrease)
2021 	2020 	2021 vs. 2020
Revenues:
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	55,486 	$ 	50,640 	$ 	4,846 	10%
Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,340 	8,431 	(91) 	(1)
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,918 	4,985 	933 	19
Investment and other income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	452 	365 	87 	24
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	70,196 	64,421 	5,775 	9
Operating costs:
Medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	44,904 	41,000 	3,904 	10
Operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,223 	10,015 	208 	2
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,572 	7,687 	(115) 	(1)
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	758 	723 	35 	5
Total operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	63,457 	59,425 	4,032 	7
Earnings from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,739 	4,996 	1,743 	35
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(397) 	(437) 	40 	(9)
Earnings before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,342 	4,559 	1,783 	39
Provision for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,364) 	(1,094) 	(270) 	25
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,978 	3,465 	1,513 	44
Earnings attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . 	(116) 	(83) 	(33) 	40
Net earnings attributable to UnitedHealth Group common shareholders . . . . . . 	$ 	4,862 	$ 	3,382 	$ 	1,480 	44%
Diluted earnings per share attributable to UnitedHealth Group common
shareholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	5.08 	$ 	3.52 	$ 	1.56 	44%
Medical care ratio (a) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	80.9% 	81.0% 	(0.1)%
Operating cost ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	14.6 	15.5 	(0.9)
Operating margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	9.6 	7.8 	1.8
Tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	21.5 	24.0 	(2.5)
Net earnings margin (b) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6.9 	5.2 	1.7
Return on equity (c) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	29.5% 	23.6% 	5.9%
(a) Medical care ratio is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average
shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year
and the shareholders’ equity balances at the end of each of the quarters in the year presented.
18

-- 20 of 30 --

2021 RESULTS OF OPERATIONS COMPARED TO 2020 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenue
The increases in revenue were primarily driven by the increase in the number of individuals served through
Medicare Advantage and Medicaid; pricing trends; and organic and acquisition growth across the Optum
business, primarily due to expansion in care delivery and managed services. The increases were partially offset
by decreased individuals served through our commercial benefits business due to the continued economic
impacts of COVID-19.
Medical Costs and MCR
Medical costs increased as a result of growth in people served through Medicare Advantage and Medicaid,
medical cost trends and COVID-19 related care and testing costs, partially offset by the temporary deferral of
care continued to be caused by COVID-19, decreased people served in commercial, increased prior year
favorable reserve development and calendar day impacts. The MCR was stable due to the temporary deferral of
care, increased prior year favorable reserve development and calendar day impacts, being offset by the
permanent repeal of the Health Insurance Tax and COVID-19 related care and testing costs.
Operating Cost Ratio
The operating cost ratio decreased primarily due to the permanent repeal of the return of the Health Insurance
Tax and operating efficiency gains, partially offset by business mix.
Income Tax Rate
Our effective tax rate decreased primarily due to the permanent repeal of the nondeductible Health Insurance
Tax.
Reportable Segments
See Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report
for more information on our segments. We utilize various metrics to evaluate and manage our reportable
segments, including individuals served by UnitedHealthcare by major market segment and funding arrangement,
people served by OptumHealth and adjusted scripts for OptumRx. These metrics are the main drivers of revenue,
earnings and cash flows at each business. The metrics also allow management and investors to evaluate and
understand business mix, customer penetration and pricing trends when comparing the metrics to revenue by
segment.
19

-- 21 of 30 --

The following table presents a summary of the reportable segment financial information:
Three Months Ended
March 31, Increase/
(Decrease)
(in millions, except percentages) 	2021 	2020 	2021 vs. 2020
Revenues
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 55,114 	$ 51,068 	$ 4,046 	8%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12,403 	9,192 	3,211 	35
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,852 	2,494 	358 	14
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	21,604 	21,557 	47 	—
Optum eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(475) 	(404) 	(71) 	18
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	36,384 	32,839 	3,545 	11
Eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(21,302) 	(19,486) 	(1,816) 	9
Consolidated revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 70,196 	$ 64,421 	$ 5,775 	9%
Earnings from operations
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	4,108 	$ 	2,888 	$ 1,220 	42%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	962 	712 	250 	35
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	779 	536 	243 	45
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	890 	860 	30 	3
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,631 	2,108 	523 	25
Consolidated earnings from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	6,739 	$ 	4,996 	$ 1,743 	35%
Operating margin
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.5% 	5.7% 	1.8%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.8 	7.7 	0.1
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	27.3 	21.5 	5.8
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4.1 	4.0 	0.1
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.2 	6.4 	0.8
Consolidated operating margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	9.6% 	7.8% 	1.8%
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
Three Months Ended
March 31, 	Increase/(Decrease)
(in millions, except percentages) 	2021 	2020 	2021 vs. 2020
UnitedHealthcare Employer & Individual . . . . . . . . . . . . . . . . . . . . . 	$ 	14,632 	$ 	14,280 	$ 	352 	2%
UnitedHealthcare Medicare & Retirement . . . . . . . . . . . . . . . . . . . . . 	25,474 	23,152 	2,322 	10
UnitedHealthcare Community & State . . . . . . . . . . . . . . . . . . . . . . . 	12,973 	11,453 	1,520 	13
UnitedHealthcare Global . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,035 	2,183 	(148) 	(7)
Total UnitedHealthcare revenues . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	55,114 	$ 	51,068 	$ 	4,046 	8%
20

-- 22 of 30 --

The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major
market segment and funding arrangement:
March 31, Increase/
(Decrease)
(in thousands, except percentages) 	2021 	2020 	2021 vs. 2020
Commercial:
Risk-based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,860 	8,215 	(355) 	(4)%
Fee-based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	18,455 	18,825 	(370) 	(2)
Total commercial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26,315 	27,040 	(725) 	(3)
Medicare Advantage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,335 	5,575 	760 	14
Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,975 	5,880 	1,095 	19
Medicare Supplement (Standardized) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,390 	4,440 	(50) 	(1)
Total community and senior . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	17,700 	15,895 	1,805 	11
Total UnitedHealthcare — domestic medical . . . . . . . . . . . . . . . . . . . . . 	44,015 	42,935 	1,080 	3
Global . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,460 	5,605 	(145) 	(3)
Total UnitedHealthcare — medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	49,475 	48,540 	935 	2%
Supplemental Data:
Medicare Part D stand-alone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,795 	4,150 	(355) 	(9)%
Fee-based and risk-based commercial business decreased primarily due to increased unemployment. Medicare
Advantage increased due to growth in people served through individual and group Medicare Advantage plans.
The increase in people served through Medicaid was primarily driven by states continuing to ease
redetermination requirements due to COVID-19, new state-based awards and growth in people served through
Dual Special Needs Plans.
UnitedHealthcare’s revenue increased due to growth in the number of individuals served through Medicare
Advantage and Medicaid and a greater mix of people with higher acuity needs, partially offset by a decrease in
the number of individuals served through commercial benefits and the permanent repeal of the Health Insurance
Tax. Earnings from operations increased due to the continued deferral of care caused by COVID-19 on the health
system, the growth in people served through Medicare Advantage and Medicaid and the repeal of the Health
Insurance Tax, partially offset by COVID-19 related care and testing costs, the reduction in people served
through commercial benefits and broader economic impacts of COVID-19.
Optum
Total revenues and earnings from operations increased due to growth at OptumHealth and OptumInsight. The
results by segment were as follows:
OptumHealth
Revenue and earnings from operations at OptumHealth increased primarily due to organic growth and
acquisitions in care delivery. Earnings from operations were also impacted by the temporary deferral of care at
our risk-based businesses caused by COVID-19 and cost management initiatives, partially offset by COVID-19
related care costs. OptumHealth served approximately 99 million people as of March 31, 2021 compared to
96 million people as of March 31, 2020.
OptumInsight
Revenue at OptumInsight increased primarily due to growth in technology and managed services, partially offset
by decreased activity levels in volume-based services due to the impact of COVID-19 on payer and care provider
clients. Earnings from operations increased primarily due to productivity gains and cost management initiatives,
as well as the factors impacting revenue.
21

-- 23 of 30 --

OptumRx
Revenue and earnings from operations at OptumRx grew modestly due to organic growth and acquisitions in
pharmacy care services and pricing trends, offset by lower script volumes. OptumRx fulfilled 329 million and
339 million adjusted scripts in the first quarters of 2021 and 2020, respectively, as the first quarter 2020 included
the advance provision of medications to people served in response to COVID-related supply concerns, with script
levels then receding with care deferral patterns.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
Three Months Ended
March 31, Increase/
(Decrease)
(in millions) 	2021 	2020 	2021 vs. 2020
Sources of cash:
Cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 6,005 	$ 	2,943 	$ 	3,062
Issuances of short-term borrowings and long-term debt, net of
repayments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,907 	10,797 	(7,890)
Proceeds from common stock issuances . . . . . . . . . . . . . . . . . . . . . . . . . . 	436 	557 	(121)
Customer funds administered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,131 	1,062 	1,069
Sales and maturities of investments, net of purchases . . . . . . . . . . . . . . . 	— 	30 	(30)
Total sources of cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,479 	15,389
Uses of cash:
Common stock repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,650) 	(1,691) 	41
Cash paid for acquisitions, net of cash assumed . . . . . . . . . . . . . . . . . . . . 	(1,193) 	(929) 	(264)
Purchases of investments, net of sales and maturities . . . . . . . . . . . . . . . 	(1,714) 	— 	(1,714)
Purchases of property, equipment and capitalized software . . . . . . . . . . . 	(568) 	(469) 	(99)
Cash dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,181) 	(1,024) 	(157)
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,088) 	(563) 	(1,525)
Total uses of cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(8,394) 	(4,676)
Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . . . . 	(51) 	(129) 	78
Net increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 3,034 	$ 10,584 	$ (7,550)
2021 Cash Flows Compared to 2020 Cash Flows
Increased cash flows provided by operating activities were primarily driven by increased net earnings and
changes in working capital accounts. Other significant changes in sources or uses of cash year-over-year included
decreased short-term borrowings and increased purchases of investments, partially offset by increased customer
funds administered.
Financial Condition
As of March 31, 2021, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of
$63.4 billion included approximately $20.0 billion of cash and cash equivalents (of which $2.1 billion was available
for general corporate use), $40.9 billion of debt securities and $2.6 billion of investments in equity securities. Given
the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the
aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our
available-for-sale debt securities portfolio had a weighted-average duration of 3.8 years and a weighted-average
credit rating of “Double A” as of March 31, 2021. When multiple credit ratings are available for an individual
security, the average of the available ratings is used to determine the weighted-average credit rating.
22

-- 24 of 30 --

Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate
use, our capital resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2020 was disclosed in Part II,
Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations ” in our
2020 10-K. During the three months ended March 31, 2021, there were no material changes to this previously
disclosed information outside the ordinary course of business. We believe our capital resources are sufficient to
meet future, short-term and long-term, liquidity needs. We continually evaluate opportunities to expand our
operations, including through internal development of new products, programs and technology applications and
acquisitions.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper
borrowing program, which facilitates the private placement of unsecured debt through independent broker-
dealers, and are available for general corporate purposes. For more information on our commercial paper and
bank credit facilities, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I,
Item 1 of this report.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a
defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of March 31, 2021, our debt to
debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 39%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate
purposes, such as, to meet our working capital requirements, to refinance debt, to finance acquisitions or for
share repurchases. For more information on our long-term debt, see Note 5 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
Credit Ratings. Our credit ratings as of March 31, 2021 were as follows:
Moody’s 	S&P Global 	Fitch 	A.M. Best
Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook
Senior unsecured debt . . . . . . . . . . . . 	A3 	Stable 	A+ 	Stable 	A 	Stable 	A- 	Positive
Commercial paper . . . . . . . . . . . . . . . 	P-2 	n/a 	A-1 	n/a 	F1 	n/a 	AMB-1 	n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our
profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions,
regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or
adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the three months ended March 31, 2021, we repurchased approximately
5 million shares at an average price of $345.42 per share. As of March 31, 2021, we had Board authorization to
purchase up to 53 million shares of our common stock.
Dividends. Our quarterly cash dividend to shareholders reflects an annual dividend rate of $5.00 per share.
Pending Acquisitions. The Company has entered into agreements to purchase companies in the health care
sector, most notably Change Healthcare (NASDAQ: CHNG), which is expected to close in the second half of
2021, subject to regulatory approvals and other customary closing conditions. The total anticipated capital
required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $12 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements in Part II,
Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” in Part II, Item 7 in our 2020 10-K.
23

-- 25 of 30 --

RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed
Consolidated Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions
and estimates, which we believe are reasonable and prudent based on the available facts and circumstances.
These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance
sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on
historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection
of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from
our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our
critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” in Part II, Item 7 in our 2020 10-K. For a detailed discussion of our significant accounting policies,
see Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in our
2020 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-
looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities
law. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,”
“should” and similar expressions identify forward-looking statements. These statements may contain information
about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results
could differ materially from those that management expects, depending on the outcome of certain factors
including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the
COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in
existing health care laws or regulations, or their enforcement or application; the DOJ’s legal action relating to the
risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting
revenue; reductions in revenue or delays to cash flows received under government programs; changes in
Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to
maintain effective and efficient information systems or if our technology products do not operate as intended;
cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; risks and
uncertainties associated with the pharmacy benefits management industry; competitive pressures; changes in or
challenges to our public sector contract awards; our ability to contract on competitive terms with physicians,
hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key
employees and executives; the impact of potential changes in tax laws and regulations (including any increase in
the U.S. income tax rate applicable to corporations); failure to achieve targeted operating cost productivity
improvements; increases in costs and other liabilities associated with litigation, government investigations, audits
or reviews; failure to manage successfully our strategic alliances or complete or receive anticipated benefits of
strategic transactions; fluctuations in foreign currency exchange rates; downgrades in our credit ratings; our
investment portfolio performance; impairment of our goodwill and intangible assets; and our ability to obtain
sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our
debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue
repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain
risks that may affect our business operations, financial condition and results of operations more fully in our
filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking
statements are not guarantees of future performance or results and are subject to risks, uncertainties and
assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations
24

-- 26 of 30 --

expressed or implied in this document or any of our prior communications. You should not place undue reliance
on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or
revise any forward-looking statements, except as required by law.
ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market
sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities,
either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in
available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield
curve by 1% point or 2% points as of March 31, 2021 on our investment income and interest expense per annum,
and the fair value of our investments and debt (in millions, except percentages):
March 31, 2021
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum (a)
Interest
Expense Per
Annum (a)
Fair Value of
Financial
Assets (b)
Fair Value of
Financial
Liabilities
2% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	468 	$ 	245 	$ 	(3,116) 	$ 	(7,467)
1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	234 	122 	(1,576) 	(4,059)
(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(80) 	(14) 	1,226 	4,741
(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(80) 	(14) 	1,689 	9,821
Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of March 31,
2021, the assumed hypothetical change in interest rates does not reflect the full 100 and 200 basis point reduction in
interest income or interest expense, as the rates are assumed not to fall below zero. As of March 31, 2021 and 2020, some
of our investments had interest rates below 2% so the assumed hypothetical change in the fair value of investments does
not reflect the full 200 basis point reduction.
ITEM 4. 	CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information
required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed,
summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and
communicated to our management, including our principal executive officer and principal financial officer, as
appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision
and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the
design and operation of our disclosure controls and procedures as of March 31, 2021. Based upon that evaluation,
our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
were effective at the reasonable assurance level as of March 31, 2021.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended March 31,
2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.
25

-- 27 of 30 --

PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 6 of Notes to the
Condensed Consolidated Financial Statements contained in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in
Part I, Item 1A, “Risk Factors” of our 2020 10-K, which could materially affect our business, financial condition
or future results. The risks described in our 2020 10-K are not the only risks facing us. Additional risks and
uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely
affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2020 10-K.
ITEM 2. 	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates
periodically. There is no established expiration date for the program. During the first quarter 2021, we
repurchased approximately 5 million shares at an average price of $345.42 per share. As of March 31, 2021, we
had Board authorization to purchase up to 53 million shares of our common stock.
26

-- 28 of 30 --

ITEM 6. 	EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K.
The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to
Exhibit 3.1 to the Company’s Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 	Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021
(incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on
Form 8-K filed on February 26, 2021)
4.1 	Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The
Bank of New York (incorporated by reference to Exhibit 4.1 to the Company’s Registration
Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
4.2 	Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998,
between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to
Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30,
2001)
4.3 	Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant
to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among
UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company
(incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2007)
4.4 	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank
National Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration
Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
31.1 	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS 	XBRL Instance Document—the instance document does not appear in the Interactive Data File
because its XBRL tags are embedded within the Inline XBRL document.
101.SCH 	Inline XBRL Taxonomy Extension Schema Document.
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
* 	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain
holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.
27

-- 29 of 30 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/ S/ 	ANDREW P. W ITTY
Andrew P. Witty
Chief Executive Officer
(principal executive officer)
Dated: May 5, 2021
/ S/ 	J OHN F. REX
John F. Rex
Executive Vice President and
Chief Financial Officer
(principal financial officer)
Dated: May 5, 2021
/ S/ 	THOMAS E. ROOS
Thomas E. Roos
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
Dated: May 5, 2021
28

-- 30 of 30 --